Medtronic announced plans to acquire U.S.-based Scientia Vascular in a deal valued at $550 million, a move aimed at expanding its range of medical devices used in stroke treatment. The transaction is expected to close during the first half of Medtronic’s fiscal 2027, with the company indicating the timeline could fall between late April and the end of October.
Scientia Vascular, headquartered in Salt Lake City and employing about 310 people, develops guidewires and catheters used to navigate blood vessels in the brain. Medtronic said these devices can be integrated into its existing portfolio of neurovascular products, which includes tools used in procedures designed to remove clots during stroke treatment.
The company said the acquisition would help broaden the set of devices available for physicians performing procedures for both hemorrhagic and acute ischemic stroke. Medtronic described Scientia’s catalog as one that could be incorporated into its current line of neurovascular interventions, including stent retrievers.
Scientia’s guidewire technology is produced by etching gaps into a solid tube of nitinol alloy. This process creates rings connected by beams, enabling the guidewire to bend and pass through small, twisted blood vessels in the brain while still allowing physicians to apply torque during procedures. The company said the approach brings benefits not seen with traditional guidewires reinforced with braids and coils.
Among the company’s products are the Aristotle guidewires, which are available in different sizes. Scientia also produces the Socrates aspiration catheter and the Plato microcatheter. The Plato device is designed to deliver embolic stents and coils, as well as liquid embolic therapies such as Medtronic’s Onyx platform. The Onyx system received an additional approval from the U.S. Food and Drug Administration late last year for the surgical treatment of subdermal hematoma.
“This acquisition positions Medtronic with a full suite of products,” said Linnea Burman, senior vice president and president of Medtronic’s Neurovascular business. She added that the deal supports procedures across both hemorrhagic and acute ischemic stroke.
Rick Randall, chief executive officer of Scientia Vascular, said the company has developed technology that physicians have adopted. He stated that the agreement would allow the company’s engineering to reach disease areas globally while also giving Medtronic a comprehensive product portfolio and a complete guidewire line.
Medtronic said the acquisition is expected to have a minimal dilutive effect on its adjusted earnings in 2027 and to become accretive in later years. The company also noted that the transaction may include potential earn-out and milestone payments after the acquisition closes, though additional details were not disclosed.
Analysts have also commented on the transaction. Leerink Partners said the deal supports Medtronic’s broader strategy of increasing growth through acquisitions and reflects confidence in Scientia’s underlying technology. Evercore ISI described the purchase as a tuck-in acquisition that strengthens Medtronic’s stroke portfolio and aligns with its current neurovascular devices.
The announcement comes after Boston Scientific earlier this year revealed a $14.5 billion agreement to acquire Penumbra. That transaction includes vascular devices used to address clots in peripheral, coronary, and pulmonary vessels, as well as stroke care products such as catheters ranging from micro to wide-bore sizes and systems designed for aspiration and reperfusion.
Medtronic shares were down more than 1% in early trading following the announcement of the acquisition.
Medtronic Strengthens Stroke Treatment Portfolio
Medtronic has announced plans to acquire Scientia Vascular in a deal valued at approximately $550 million.
Medtronic has announced plans to acquire Scientia Vascular in a deal valued at approximately $550 million, aiming to strengthen its presence in the growing neurovascular treatment market. The acquisition will allow the medical technology company to expand its range of devices used in stroke and other complex brain vessel procedures. By integrating Scientia Vascular’s advanced guidewire and catheter technologies, the company hopes to provide physicians with more precise tools for navigating delicate brain arteries during minimally invasive interventions.
The transaction reflects a broader strategy to enhance innovation in stroke treatment and support healthcare providers with more comprehensive neurovascular solutions. Scientia Vascular specializes in micro-technology designed for accessing small and complex blood vessels in the brain, which are often involved in conditions such as aneurysms and ischemic strokes. Industry analysts believe the acquisition could help strengthen the company’s competitive position in the rapidly expanding market for neurovascular devices, while also improving treatment options for patients suffering from severe neurological emergencies.
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
